PEL
MCID: PRM042
MIFTS: 53

Primary Effusion Lymphoma (PEL) malady

Categories: Rare diseases, Blood diseases, Immune diseases

Aliases & Classifications for Primary Effusion Lymphoma

Aliases & Descriptions for Primary Effusion Lymphoma:

Name: Primary Effusion Lymphoma 50 56 69
Pel 50 56
Body Cavity-Based Lymphoma 56
Lymphoma, Aids-Related 69
Aids-Related Lymphoma 50
Lymphoma Aids-Related 52

Characteristics:

Orphanet epidemiological data:

56
primary effusion lymphoma
Age of onset: Adult; Age of death: adult;

Classifications:



External Ids:

Orphanet 56 ORPHA48686
MESH via Orphanet 43 D054685
UMLS via Orphanet 70 C1292753
ICD10 via Orphanet 34 C83.8

Summaries for Primary Effusion Lymphoma

MalaCards based summary : Primary Effusion Lymphoma, also known as pel, is related to human herpesvirus 8 and kaposi sarcoma, and has symptoms including pericardial effusion, abdominal pain and dyspnea. An important gene associated with Primary Effusion Lymphoma is MYC (MYC Proto-Oncogene, BHLH Transcription Factor), and among its related pathways/superpathways are ERK Signaling and PEDF Induced Signaling. The drugs Etoposide and Methotrexate have been mentioned in the context of this disorder. Affiliated tissues include b cells, t cells and liver, and related phenotypes are Synthetic lethal with MLN4924 (a NAE inhibitor) and hematopoietic system

Wikipedia : 71 Primary effusion lymphoma (PEL) is a B-cell lymphoma, presenting with a malignant effusion without a... more...

Related Diseases for Primary Effusion Lymphoma

Diseases related to Primary Effusion Lymphoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 88)
id Related Disease Score Top Affiliating Genes
1 human herpesvirus 8 11.4
2 kaposi sarcoma 11.3
3 plasmablastic lymphoma 11.3
4 lymphoma aids related 11.1
5 lymphoma 10.9
6 sarcoma 10.5
7 senile atrophy of choroid 10.2 CASP3 VEGFA
8 craniosynostosis, type 1 10.2 IL6 VEGFA
9 pyloric antrum cancer 10.2 BCL6 VEGFA
10 degenerative disc disease 10.2 IL6 VEGFA
11 penile disease 10.1 BCL6 IRF4
12 cardiac tuberculosis 10.1 IL6 VEGFA
13 bipolar i disorder 10.1 IL6 VEGFA
14 adult medulloblastoma 10.1 CASP3 MYC VEGFA
15 hepatitis 10.1
16 trachea squamous cell carcinoma 10.1 CASP3 MYC VEGFA
17 melanoma metastasis 10.1 BCL6 CASP3 MYC
18 bardet-biedl syndrome 10.1 CASP3 MYC VEGFA
19 malignant pleural solitary fibrous tumor 10.1 CASP3 MYC VEGFA
20 gingival recession 10.1 BCL6 IRF4 MYC
21 ectodermal dysplasia 10.1 BCL6 IRF4 MYC
22 tall cell variant papillary carcinoma 10.1 BCL6 IL6 MYC
23 anterior foramen magnum meningioma 10.1 BCL6 IL6 MYC
24 conjugate gaze palsy 10.1 IL6 VEGFA
25 vogt-koyanagi-harada disease 10.1 CASP3 IL6 VEGFA
26 b-cell lymphomas 10.0
27 hepatitis c 10.0
28 angular blepharoconjunctivitis 10.0 IL6 VEGFA
29 larynx carcinoma in situ 10.0 CASP3 IL6
30 hepatitis c virus 10.0
31 thanatophoric dysplasia, type ii 10.0 BIRC5 CASP3 MYC
32 retinal degeneration 10.0 IL6 VEGFA
33 bleeding disorder, platelet-type, 18 10.0 CASP3 MYC TNFSF10
34 marginal zone b-cell lymphoma 10.0 TNFRSF10B TNFSF10 VEGFA
35 uvula cancer 10.0 TNFRSF10B TNFSF10 VEGFA
36 substance-induced psychosis 10.0 CASP3 IL6 VEGFA
37 carnitine-acylcarnitine translocase deficiency 10.0 BCL6 IL6 IRF4
38 peritonitis 10.0
39 liver cirrhosis 10.0
40 bladder disease 10.0 BCL6 CASP3 IRF4 MYC
41 castleman disease 9.9
42 multicentric castleman disease 9.9
43 proctitis 9.9 CASP3 IL6 MYC VEGFA
44 cryptosporidiosis 9.9 IL6 VEGFA
45 thoracic outlet syndrome 9.9 CASP3 CDK2 MYC
46 glucose-6-phosphate translocase deficiency 9.9 CDK2 MYC VEGFA
47 nail disorder, nonsyndromic congenital, 3, 9.9 CASP3 IL6 MYC VEGFA
48 adult astrocytic tumour 9.9 CDK2 MYC VEGFA
49 endotheliitis 9.9
50 hepatitis b 9.8

Graphical network of the top 20 diseases related to Primary Effusion Lymphoma:



Diseases related to Primary Effusion Lymphoma

Symptoms & Phenotypes for Primary Effusion Lymphoma

Human phenotypes related to Primary Effusion Lymphoma:

56 32 (show all 8)
id Description HPO Frequency Orphanet Frequency HPO Source Accession
1 pericardial effusion 56 32 Very frequent (99-80%) HP:0001698
2 abdominal pain 56 32 Very frequent (99-80%) HP:0002027
3 dyspnea 56 32 Very frequent (99-80%) HP:0002094
4 pleural effusion 56 32 Very frequent (99-80%) HP:0002202
5 abnormality of the peritoneum 56 32 Very frequent (99-80%) HP:0002585
6 immunodeficiency 56 32 Frequent (79-30%) HP:0002721
7 abdominal distention 56 32 Very frequent (99-80%) HP:0003270
8 b-cell lymphoma 56 32 Very frequent (99-80%) HP:0012191

GenomeRNAi Phenotypes related to Primary Effusion Lymphoma according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.64 BIRC5 CASP3 CDK2 TNFRSF10B TNFSF10
2 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.64 BIRC5 CASP3 CDK2 TNFRSF10B TNFSF10 MYC
3 Increased cell death HMECs cells GR00103-A-0 9.35 CDK2 MYC BCL6 BIRC5 CASP3

MGI Mouse Phenotypes related to Primary Effusion Lymphoma:

44 (show all 11)
id Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.09 BCL6 BIRC5 CASP3 CDK2 IL6 IRF4
2 endocrine/exocrine gland MP:0005379 10.06 BCL6 BIRC5 CASP3 CDK2 IL6 MYC
3 cardiovascular system MP:0005385 10.04 BCL6 CASP3 CDK2 IL6 MYC TNFSF10
4 cellular MP:0005384 10.02 BCL6 BIRC5 CASP3 CDK2 IL6 MYC
5 immune system MP:0005387 10.02 IRF4 MYC TNFSF10 VEGFA BCL6 BIRC5
6 homeostasis/metabolism MP:0005376 10.01 BCL6 BIRC5 CASP3 CDK2 IL6 MYC
7 mortality/aging MP:0010768 9.86 IL6 MYC TNFSF10 VEGFA BCL6 BIRC5
8 liver/biliary system MP:0005370 9.8 BCL6 CDK2 IL6 MYC TNFSF10 VEGFA
9 muscle MP:0005369 9.63 MYC VEGFA BCL6 CASP3 CDK2 IL6
10 neoplasm MP:0002006 9.43 CDK2 IL6 IRF4 MYC TNFSF10 VEGFA
11 reproductive system MP:0005389 9.1 BCL6 CASP3 CDK2 IL6 MYC VEGFA

Drugs & Therapeutics for Primary Effusion Lymphoma

Drugs for Primary Effusion Lymphoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 116)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Etoposide Approved Phase 3,Phase 2,Phase 1 33419-42-0 36462
2
Methotrexate Approved Phase 3,Phase 2 1959-05-2, 59-05-2 126941
3
Cyclophosphamide Approved, Investigational Phase 3,Phase 2,Phase 1 50-18-0, 6055-19-2 2907
4
Busulfan Approved, Investigational Phase 3,Phase 2 55-98-1 2478
5
Miconazole Approved, Investigational, Vet_approved Phase 3,Phase 2 22916-47-8 4189
6
Doxycycline Approved, Investigational, Vet_approved Phase 3 564-25-0 54671203
7
Povidone-iodine Approved Phase 3 25655-41-8
8
Cyclosporine Approved, Investigational, Vet_approved Phase 3,Phase 2 79217-60-0, 59865-13-3 5284373 6435893
9
Mesna Approved Phase 3 3375-50-6 598
10
leucovorin Approved, Nutraceutical Phase 3,Phase 2 58-05-9 54575, 6560146 143
11
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 2 59-30-3 6037
12 Alkylating Agents Phase 3,Phase 2,Phase 1
13 Folic Acid Antagonists Phase 3,Phase 2
14 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1
15 Nucleic Acid Synthesis Inhibitors Phase 3,Phase 2
16 Dermatologic Agents Phase 3,Phase 2,Phase 1
17 Vitamin B Complex Phase 3,Phase 2
18 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1
19 Etoposide phosphate Phase 3,Phase 2,Phase 1
20 Anti-Infective Agents Phase 3,Phase 2,Phase 1,Early Phase 1
21 Immunosuppressive Agents Phase 3,Phase 2,Phase 1
22 Protective Agents Phase 3,Phase 2
23 Antifungal Agents Phase 3,Phase 2
24 Antimalarials Phase 3,Phase 2
25 Antimetabolites Phase 3,Phase 2
26 Antimetabolites, Antineoplastic Phase 3,Phase 2
27 Antirheumatic Agents Phase 3,Phase 2,Phase 1
28 Antineoplastic Agents, Alkylating Phase 3,Phase 2,Phase 1
29 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Phase 1
30 Antiparasitic Agents Phase 3,Phase 2
31 Antiprotozoal Agents Phase 3,Phase 2
32
Bilirubin Phase 3 635-65-4 5280352
33 Calcineurin Inhibitors Phase 3,Phase 2
34 Folate Nutraceutical Phase 3,Phase 2
35 Vitamin B9 Nutraceutical Phase 3,Phase 2
36
Doxorubicin Approved, Investigational Phase 2,Phase 1 23214-92-8 31703
37
Vincristine Approved, Investigational Phase 2,Phase 1 2068-78-2, 57-22-7 5978
38
Cisplatin Approved Phase 2 15663-27-1 84093 441203 2767
39
Cytarabine Approved, Investigational Phase 2 147-94-4 6253
40
Efavirenz Approved, Investigational Phase 2 154598-52-4 64139
41
Zidovudine Approved Phase 2 30516-87-1 35370
42
Ganciclovir Approved, Investigational Phase 2 82410-32-0 3454
43
Allopurinol Approved Phase 2 315-30-0 2094
44
rituximab Approved Phase 2,Phase 1 174722-31-7 10201696
45
Bleomycin Approved Phase 2 11056-06-7 5360373
46
Ifosfamide Approved Phase 2 3778-73-2 3690
47
Procarbazine Approved Phase 2 671-16-9 4915
48
Bortezomib Approved, Investigational Phase 2 179324-69-7 387447 93860
49
Prednisolone Approved, Vet_approved Phase 2 50-24-8 5755
50
Sulfamethoxazole Approved Phase 2 723-46-6 5329

Interventional clinical trials:

(show all 35)
id Name Status NCT ID Phase
1 A Study to Compare the Efficacy and Safety of Intrapleural Doxycycline Versus Iodopovidone for Performing Pleurodesis in Malignant Pleural Effusion Recruiting NCT02583282 Phase 3
2 Chemotherapy With or Without Total-Body Irradiation Prior to Bone Marrow Transplantation in Treating Children With Acute Lymphoblastic Leukemia Terminated NCT00002961 Phase 3
3 Bortezomib and Antiviral Therapy Followed By Effusion Drainage, Bevacizumab, and Combination Chemotherapy in Treating Patients With Primary Effusion Lymphoma Completed NCT00217503 Phase 2
4 Combination Chemotherapy in Treating Patients With AIDS-Related Lymphoma Completed NCT00002524 Phase 2
5 SWOG-9320 Combination Chemotherapy, Radiation Therapy, and Antiviral Therapy in Treating Patients With AIDS-Related Lymphoma Completed NCT00002571 Phase 2
6 Chemotherapy Followed By Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Refractory AIDS-Related Lymphoma Completed NCT00005824 Phase 2
7 EPOCH Chemotherapy +/- IL-12 for Previously Untreated and EPOCH Plus Rituximab for Previously Treated Patients With AIDS-Associated Lymphoma Completed NCT00001563 Phase 2
8 Combination Chemotherapy in Treating Patients With AIDS-Related Lymphoma Completed NCT00003388 Phase 2
9 A Feasibility Study of Co-administering Combination Antiretroviral Therapy (cART) and R-EPOCH Chemotherapy for the Management of ARL Completed NCT00799136 Phase 2
10 High-dose Chemotherapy With Transplantation of Gene-modified Haematopoietic Stem Cells for HIV-positive Patients With Malignant Diseases Indicating an HSCT Completed NCT00858793 Phase 1, Phase 2
11 Combination Chemotherapy in Treating Patients With AIDS-Related Hodgkin's Disease Completed NCT00003114 Phase 2
12 Lenalidomide Combined With Modified DA-EPOCH and Rituximab (EPOCH-R2) in Primary Effusion Lymphoma or KSHV-associated Large Cell Lymphoma Recruiting NCT02911142 Phase 1, Phase 2
13 Intravenous Chemotherapy or Oral Chemotherapy in Treating Patients With Previously Untreated Stage III-IV HIV-Associated Non-Hodgkin Lymphoma Recruiting NCT01775475 Phase 2
14 Vorinostat and Combination Chemotherapy With Rituximab in Treating Patients With HIV-Related Diffuse Large B-Cell Non-Hodgkin Lymphoma or Other Aggressive B-Cell Lymphomas Active, not recruiting NCT01193842 Phase 1, Phase 2
15 Nivolumab With or Without Varlilumab in Treating Patients With Relapsed or Refractory Aggressive B-cell Lymphomas Not yet recruiting NCT03038672 Phase 2
16 Pegylated Liposomal Doxorubicin (Doxil) With Rituximab in Relapsed AIDS-Related Non-Hodgkin's Lymphomas Terminated NCT00183976 Phase 2
17 Efficacy of Rituximab and Cyclophosphamide, Doxorubicin, Vincristine, Prednisone (CHOP) in Patients With HIV Associated Non-Hodgkin’s Lymphoma Terminated NCT00126243 Phase 2
18 Study of Pomalidomide Combined With Modified DA-EPOCH and Rituximab in KSHV-Associated Lymphomas Withdrawn NCT02228512 Phase 1, Phase 2
19 Peripheral Stem Cell Transplantation Followed By Infusion of White Blood Cells in Treating Patients With AIDS-Related Lymphoma Withdrawn NCT00024128 Phase 2
20 Combination Chemotherapy Followed by Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed or Refractory AIDS-Related Non-Hodgkin's Lymphoma Withdrawn NCT00310128 Phase 2
21 Study to Evaluate Safety and Tolerability of XmAb13676 in Patients With CD20-expressing Hematologic Malignancies Recruiting NCT02924402 Phase 1
22 Study of Genes and Environment in Patients With Cancer in East Anglia, Trent, or West Midlands Regions of the United Kingdom Unknown status NCT00757614
23 Seroprevalence of Kaposi's Sarcoma Herpes Virus in the United States Completed NCT00026728
24 Procurement of Follicular B Cell Lymphoma Cells for the Purpose of Possible Use in Future Clinical Trials Completed NCT00487513
25 Chemotherapy and Azidothymidine, With or Without Radiotherapy, for High Grade Lymphoma in AIDS-Risk Group Members Completed NCT00000703
26 Clinical Factors and Gene Expression Analysis for Prognosis in Tissue Samples From Patients With AIDS-Related Primary Effusion Lymphoma Recruiting NCT02823327
27 Gene Therapy After Frontline Chemotherapy in Treating Patients With AIDS-Related Non-Hodgkin Lymphoma Recruiting NCT01961063
28 Specimen Collections From Patients With HIV Infection, KSHV Infection, Viral-Related Pre-malignant Lesions and Cancer Recruiting NCT00006518
29 Gene Therapy and Combination Chemotherapy in Treating Patients With AIDS-Related Non-Hodgkin Lymphoma Recruiting NCT02337985
30 Salvia Hispanica Seed in Reducing Risk of Disease Recurrence in Patients With Non-Hodgkin Lymphoma Recruiting NCT02652715
31 124I-FIAU Imaging in EBV and KSHV Associated Cancers Recruiting NCT00982449 Early Phase 1
32 Extended Analysis for Leukemia/Lymphoma Treatment Recruiting NCT03096821
33 Gene Therapy-Treated Stem Cells in Treating Patients Undergoing Stem Cell Transplant for Intermediate-Grade or High-Grade AIDS-Related Lymphoma Active, not recruiting NCT00569985
34 Genetically Modified Peripheral Blood Stem Cell Transplant in Treating Patients With HIV-Associated Non-Hodgkin or Hodgkin Lymphoma Withdrawn NCT01769911
35 Aprepitant or Ondansetron in Treating Nausea and Vomiting Caused By Opioids in Patients With Cancer Withdrawn NCT00499668

Search NIH Clinical Center for Primary Effusion Lymphoma

Genetic Tests for Primary Effusion Lymphoma

Anatomical Context for Primary Effusion Lymphoma

MalaCards organs/tissues related to Primary Effusion Lymphoma:

39
B Cells, T Cells, Liver, Endothelial, Heart, Brain, Testis

Publications for Primary Effusion Lymphoma

Articles related to Primary Effusion Lymphoma:

(show top 50) (show all 378)
id Title Authors Year
1
Talc pleurodesis allows long-term remission in HIV-unrelated Human Herpesvirus 8-associated primary effusion lymphoma. ( 28084853 )
2017
2
Quercetin induces apoptosis and autophagy in primary effusion lymphoma cells by inhibiting PI3K/AKT/mTOR and STAT3 signaling pathways. ( 28092744 )
2017
3
Effects of ER stress on unfolded protein responses, cell survival, and viral replication in primary effusion lymphoma. ( 26692493 )
2016
4
Human Herpesvirus 8-Unrelated Primary Effusion Lymphoma-Like Lymphoma (PEL-LL) in an Elderly Korean Patient with a Good Response to Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisolone. ( 27283030 )
2016
5
Human Herpesvirus Type 8-associated Large B-cell Lymphoma: A Nonserous Extracavitary Variant of Primary Effusion Lymphoma in anA HIV-infected Man: A Case Report and ReviewA ofA the Literature. ( 27234438 )
2016
6
Classic and extracavitary primary effusion lymphoma in 51 HIV-infected patients from a single institution. ( 26799611 )
2016
7
PEGylated siRNA lipoplexes for silencing of BLIMP-1 in Primary Effusion Lymphoma: In vitro evidences of antitumoral activity. ( 26625717 )
2016
8
A potential role of the NOD genetic background in mouse peritoneal macrophages for the development of primary effusion lymphoma. ( 26859781 )
2016
9
Primary effusion lymphoma and concurrent progressive Kaposi sarcoma associated with elevated interleukin-6. ( 28092896 )
2016
10
Management and Outcomes of HIV-Associated Primary Effusion Lymphoma: A Single Center Experience. ( 27521315 )
2016
11
A role for MALT1 activity in Kaposi's sarcoma-associated herpes virus latency and growth of primary effusion lymphoma. ( 27538487 )
2016
12
Azidothymidine Sensitizes Primary Effusion Lymphoma Cells to Kaposi Sarcoma-Associated Herpesvirus-Specific CD4+ T Cell Control and Inhibits vIRF3 Function. ( 27893813 )
2016
13
Human Herpes Virus 8 Unrelated Bilateral Primary Effusion Lymphoma in a Patient With Chronic Fluid Overload. ( 27021141 )
2016
14
Diagnostic pitfall: primary effusion lymphoma with rare cytokeratin immunoreactivity. ( 28092872 )
2016
15
Triptolide decreases expression of latency-associated nuclear antigen 1 and reduces viral titers in Kaposi's sarcoma-associated and herpesvirus-related primary effusion lymphoma cells. ( 26821279 )
2016
16
Clinical characteristics and survival outcome of primary effusion lymphoma: A review of 105 patients. ( 27859456 )
2016
17
Human herpesvirus-8-unrelated primary effusion lymphoma of the elderly not associated with an increased serum lactate dehydrogenase level: A benign sub-group of effusion lymphoma without chemotherapy. ( 26727336 )
2016
18
Inhibition of autophagy by chloroquine induces apoptosis in primary effusion lymphoma in vitro and in vivo through induction of endoplasmic reticulum stress. ( 27484211 )
2016
19
Primary effusion lymphoma involving cerebrospinal fluid, deep cervical lymph nodes and adenoids. Report of a case supporting the lymphatic connection between brain and lymph nodes. ( 27862361 )
2016
20
Triptolide inhibits transcription of hTERT through down-regulation of transcription factor specificity protein 1 in primary effusion lymphoma cells. ( 26631963 )
2016
21
Extracavitary primary effusion lymphoma associated with hemophagocytic lymphohistiocytosis. ( 27414752 )
2016
22
Primary Effusion Lymphoma-like Lymphoma in a Patient with Neurofibromatosis Type 1. ( 27628603 )
2016
23
Successful Treatment of immune Reconstitution Inflammatory syndrome-related Hemophagocytic Syndrome in an HIV Patient with Primary Effusion Lymphoma. ( 28090281 )
2016
24
Diallyl trisulfide induces apoptosis by suppressing NF-I_B signaling through destabilization of TRAF6 in primary effusion lymphoma. ( 26647777 )
2016
25
Establishing and characterizing a new primary effusion lymphoma cell line harboring Kaposi's sarcoma-associated herpesvirus. ( 27536332 )
2016
26
Primary Effusion Lymphoma (PEL)-Like Lymphoma in a Child With Congenital Immunodeficiency. ( 27186682 )
2016
27
Primary Effusion Lymphoma: Is Dose-Adjusted-EPOCH Worthwhile Therapy? ( 27462227 )
2016
28
Extracavitary/solid variant of primary effusion lymphoma presenting as a gastric mass. ( 26407759 )
2015
29
Extracavitary primary effusion lymphoma: A case report from India. ( 26549075 )
2015
30
Fumagillin, a potent angiogenesis inhibitor, induces Kaposi sarcoma-associated herpesvirus replication in primary effusion lymphoma cells. ( 26093300 )
2015
31
Primary effusion lymphoma. ( 26942240 )
2015
32
Immunomodulatory drugs target IKZF1-IRF4-MYC axis in primary effusion lymphoma in a cereblon-dependent manner and display synergistic cytotoxicity with BRD4 inhibitors. ( 26119939 )
2015
33
An Unusual Case of Invasive Kaposi's Sarcoma with Primary Effusion Lymphoma in an HIV Positive Patient: Case Report and Literature Review. ( 26550504 )
2015
34
Human Immunodeficiency Virus-associated primary effusion lymphoma: An exceedingly rare entity in cerebrospinal fluid. ( 26604975 )
2015
35
Targeting HGF/c-MET induces cell cycle arrest, DNA damage and apoptosis for primary effusion lymphoma. ( 26531163 )
2015
36
Primary Effusion Lymphoma: Cytological Diagnosis of a Rare Entity--Report of Two Cases in HIV-Uninfected Patients from a Single Institution. ( 26658724 )
2015
37
Nutlin-3 loaded nanocarriers: Preparation, characterization and in vitro antineoplastic effect against primary effusion lymphoma. ( 25987470 )
2015
38
Antineoplastic effects of liposomal short interfering RNA treatment targeting BLIMP1/PRDM1 in primary effusion lymphoma. ( 26206802 )
2015
39
Constitutive Activation of Interleukin-13/STAT6 Contributes to Kaposi's Sarcoma-Associated Herpesvirus-Related Primary Effusion Lymphoma Cell Proliferation and Survival. ( 26246572 )
2015
40
HIV-associated primary effusion lymphoma presenting as a paracardial mass. ( 25725030 )
2015
41
T-cell primary effusion lymphoma with pseudo-monoclonal rearrangements for immunoglobulin heavy chain. ( 26734695 )
2015
42
A rare case of bilateral chylothorax: a diagnostic challenge--follicular lymphoma versus primary effusion lymphoma. ( 26282457 )
2015
43
Analysis of mutational signatures in exomes from B-cell lymphoma cell lines suggest APOBEC3 family members to be involved in the pathogenesis of primary effusion lymphoma. ( 25650088 )
2015
44
Human herpes virus 8-unrelated primary effusion lymphoma-like lymphoma in the pericardium: A case with latency type III Epstein-Barr virus infection showing good prognosis without chemotherapy. ( 26384578 )
2015
45
Reversal of the glycolytic phenotype of primary effusion lymphoma cells by combined targeting of cellular metabolism and PI3K/Akt/ mTOR signaling. ( 26575168 )
2015
46
Resveratrol induces cell death and inhibits human herpesvirus 8 replication in primary effusion lymphoma cells. ( 26549478 )
2015
47
Human Herpesvirus 8-Related Primary Effusion Lymphoma After Liver Transplantation. ( 25988353 )
2015
48
Human Herpesvirus 8 Interleukin-6 Contributes to Primary Effusion Lymphoma Cell Viability via Suppression of Proapoptotic Cathepsin D, a Cointeraction Partner of Vitamin K Epoxide Reductase Complex Subunit 1 Variant 2. ( 24198402 )
2014
49
Primary effusion lymphoma with aberrant T-cell phenotype in an iatrogenically immunosuppressed renal transplant male: Cytologic diagnosis in peritoneal fluid. ( 24644156 )
2014
50
Extracavitary primary effusion lymphoma presenting as a cutaneous tumor: a case report and literature review. ( 24917369 )
2014

Variations for Primary Effusion Lymphoma

Copy number variations for Primary Effusion Lymphoma from CNVD:

7
id CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 25103 1 184000000 197500000 Gain primary effusion lymphomas
2 189792 4 78400000 172200000 Gain primary effusion lymphomas
3 239813 8 41800000 84900000 Gain primary effusion lymphomas
4 262574 X 37500000 98200000 Gain primary effusion lymphomas

Expression for Primary Effusion Lymphoma

Search GEO for disease gene expression data for Primary Effusion Lymphoma.

Pathways for Primary Effusion Lymphoma

Pathways related to Primary Effusion Lymphoma according to GeneCards Suite gene sharing:

(show all 40)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
13.65 CASP3 CDK2 IL6 MYC TNFRSF10B TNFSF10
2
Show member pathways
13.47 CASP3 IL6 MYC TNFRSF10B TNFSF10 VEGFA
3
Show member pathways
13.11 BCL6 BIRC5 CASP3 IL6 IRF4 MYC
4
Show member pathways
12.8 BCL6 BIRC5 CDK2 TNFRSF10B
5
Show member pathways
12.76 BIRC5 CASP3 CDK2 IL6 MYC
6
Show member pathways
12.71 CASP3 IL6 TNFRSF10B TNFSF10
7
Show member pathways
12.64 CASP3 CDK2 IL6 TNFRSF10B TNFSF10
8
Show member pathways
12.63 CASP3 TNFRSF10B TNFSF10 VEGFA
9
Show member pathways
12.59 BIRC5 CASP3 IRF4 MYC TNFRSF10B TNFSF10
10
Show member pathways
12.45 CASP3 TNFRSF10B TNFSF10 VEGFA
11 12.43 CDK2 IL6 MYC VEGFA
12 12.4 BIRC5 CASP3 CDK2 IL6 MYC VEGFA
13
Show member pathways
12.23 BCL6 IRF4 MYC
14
Show member pathways
12.23 CASP3 CDK2 MYC TNFRSF10B
15
Show member pathways
12.2 BIRC5 CASP3 MYC
16 12.15 CASP3 MYC VEGFA
17
Show member pathways
12.14 CASP3 TNFRSF10B TNFSF10
18
Show member pathways
12.11 CASP3 CDK2 VEGFA
19
Show member pathways
12.1 CASP3 CDK2 TNFRSF10B TNFSF10
20 12.08 BCL6 IL6 MYC
21
Show member pathways
12.03 CASP3 CDK2 MYC
22 12.03 BIRC5 CASP3 MYC TNFRSF10B TNFSF10
23 12.02 CASP3 IL6 VEGFA
24 11.98 CASP3 CDK2 MYC VEGFA
25
Show member pathways
11.92 BCL6 CDK2 IL6 TNFSF10
26 11.91 IL6 MYC VEGFA
27 11.87 BIRC5 CASP3 IL6 MYC VEGFA
28
Show member pathways
11.81 BCL6 BIRC5 TNFRSF10B
29 11.81 CASP3 CDK2 IL6 MYC
30 11.76 CASP3 IL6 VEGFA
31
Show member pathways
11.55 BIRC5 IL6 VEGFA
32 11.42 CDK2 MYC VEGFA
33 11.38 CASP3 CDK2 MYC
34 11.25 BIRC5 CDK2 MYC
35 11.24 BIRC5 VEGFA
36 11.21 IL6 MYC
37 11.16 BCL6 BIRC5 IL6 IRF4 MYC VEGFA
38 11.08 CASP3 IL6 TNFRSF10B TNFSF10
39 11.06 BIRC5 CASP3 IL6 MYC VEGFA
40
Show member pathways
10.98 MYC TNFSF10

GO Terms for Primary Effusion Lymphoma

Biological processes related to Primary Effusion Lymphoma according to GeneCards Suite gene sharing:

(show all 22)
id Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription, DNA-templated GO:0045893 9.88 CDK2 IL6 IRF4 MYC
2 cellular response to DNA damage stimulus GO:0006974 9.83 BCL6 CASP3 CDK2 MYC
3 regulation of cell proliferation GO:0042127 9.77 BCL6 IL6 TNFRSF10B
4 positive regulation of apoptotic process GO:0043065 9.76 BCL6 CASP3 IL6 TNFSF10
5 response to lipopolysaccharide GO:0032496 9.74 CASP3 IL6 TNFRSF10B
6 response to amino acid GO:0043200 9.61 CASP3 IL6
7 activation of cysteine-type endopeptidase activity involved in apoptotic process GO:0006919 9.61 CASP3 TNFRSF10B TNFSF10
8 negative regulation of extrinsic apoptotic signaling pathway via death domain receptors GO:1902042 9.59 TNFRSF10B TNFSF10
9 response to antibiotic GO:0046677 9.58 CASP3 IL6
10 response to wounding GO:0009611 9.58 CASP3 IL6 MYC
11 positive regulation of DNA binding GO:0043388 9.56 IRF4 MYC
12 regulation of apoptotic process GO:0042981 9.56 BCL6 BIRC5 IL6 TNFRSF10B
13 positive regulation of mesenchymal cell proliferation GO:0002053 9.55 MYC VEGFA
14 positive regulation of cell proliferation GO:0008284 9.55 BIRC5 CDK2 IL6 MYC VEGFA
15 defense response to protozoan GO:0042832 9.54 IL6 IRF4
16 regulation of extrinsic apoptotic signaling pathway via death domain receptors GO:1902041 9.51 TNFRSF10B TNFSF10
17 positive regulation of epithelial cell proliferation GO:0050679 9.5 IL6 MYC VEGFA
18 activation of cysteine-type endopeptidase activity involved in apoptotic signaling pathway GO:0097296 9.49 TNFRSF10B TNFSF10
19 positive regulation of cellular component movement GO:0051272 9.48 BCL6 VEGFA
20 T-helper 17 cell lineage commitment GO:0072540 9.37 IL6 IRF4
21 negative regulation of apoptotic process GO:0043066 9.1 BCL6 BIRC5 CASP3 IL6 MYC VEGFA
22 cellular response to prolactin GO:1990646 8.96 IL6 MYC

Molecular functions related to Primary Effusion Lymphoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 9.32 BCL6 BIRC5 CASP3 CDK2 IL6 IRF4
2 cytokine activity GO:0005125 9.13 IL6 TNFSF10 VEGFA

Sources for Primary Effusion Lymphoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....